Triptan-induced contractile (5-HTIB receptor) responses in human cerebral and coronary arteries: Relationship to clinical effect

Clinical Science

Volumn 109, Issue 3, 2005, Pages 335-342

  Edvinsson, Lars ^a   Uddman, Erik ^a   Wackenfors, Angelica ^a   Davenport, Anthony ^b   Longmore, Jenny ^c   Malmsjö, Malin ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

5 HT (5 hydroxytryptamine) receptor; Cerebral artery; Coronary artery; In vitro pharmacology; Plasma concentration; Smooth muscle; Triptan

Indexed keywords

ELETRIPTAN; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SUMATRIPTAN; VASOCONSTRICTOR AGENT; ZOLMITRIPTAN;

ADULT; ARTICLE; BRAIN ARTERY; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; VASOCONSTRICTION;

ADULT; CEREBRAL ARTERIES; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRROLIDINES; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN AGONISTS; SUMATRIPTAN; TRIAZOLES; TRYPTAMINES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASOMOTOR SYSTEM;

EID: 25144453767     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20050016     Document Type: Article

References (36)

1. Tfelt-Hansen, P., De Vries, P. and Saxena, P. R. (2000) Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60, 1259-1287
2. 1D receptor antagonists and in situ hybridization. Cephalalgia 22, 83-93
3. Massen Van Den Brink, A., van den Broek, R. W., de Vries, R. et al. (2000) Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 55, 1524-1530
4. Nilsson, T., Longmore, J., Shaw, D. et al. (1999) Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur. J. Pharmacol. 372, 49-56
5. 1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br. J. Pharmacol. 128, 1133-1140
6. 1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 17, 833-842
7. 1B-receptors. Br. J. Clin. Pharmacol. 46, 577-582
8. Perren, M. J., Feniuk, W. and Humphrey, P. P. (1989) The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia 9 (Suppl. 9), 41-46
9. Hoyer, D., Clarke, D. E., Fozard, J. R. et al. (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46, 157-203
10. 1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br. J. Pharmacol. 129, 501-508
11. 1F receptor agonist LY334370. Cephalalgia 19, 851-858
12. Hamel, E., Fan, E., Linville, D. et al. (1993) Expression of mRNA for the serotonin 5-hydroxytryptamine1Dβ receptor subtype in human and bovine cerebral arteries. Mol. Pharmacol. 44, 242-246
13. Ennis, M. D., Ghazal, N. B., Hoffman, R. L. et al. (1998) Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects. J. Med. Chem. 41, 2180-2183
14. Longmore, J., Maguire, J. J., MacLeod, A. et al. (2000) Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery. Br. J. Clin. Pharmacol. 49, 126-131
15. Gomez-Mancilla, B., Cutler, N. R., Leibowitz, M. T. et al. (2001) Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia 21, 727-732
16. Bouchelet, I., Cohen, Z., Case, B., Seguela, P. and Hamel, E. (1996) Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol. Pharmacol. 50, 219-223
17. Rebeck, G. W., Maynard, K. I., Hyman, B. T. and Moskowitz, M. A. (1994) Selective 5-HT1Dα serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development. Proc. Natl. Acad. Sci. U.S.A. 91, 3666-3669
18. 1D receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res. 909, 112-120
19. Williamson, D. J., Shepheard, S. L., Hill, R. G. and Hargreaves, R. J. (1997) The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur. J. Pharmacol. 328, 61-64
20. Smith, D., Hill, R. G., Edvinsson, L. and Longmore, J. (2002) An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia 22, 424-431
21. Verheggen, R., Hundeshagen, A. G., Brown, A. M., Schindler, M. and Kaumann, A. J. (1998) 5-HT1B receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression. Br. J. Pharmacol. 124, 1345-1354
22. Tfelt-Hansen, P., Jansen-Olesen, I., Mortensen, A. and Edvinsson, L. (1997) Variability of vascular receptors on the human cerebral arteries as determined in vitro. In Headache Pathogenesis: Monoamines, Neuropeptides, Purines, and Nitric Oxide, vol. 7 (Olesen, J. and Edvinsson, L., eds.), pp. 173-176, Lippincott-Raven, Philadelphia
23. Tfelt-Hansen, E. L. (1997) Variability of vascular alpha-adrenoceptors on human omental vessels: an in vitro study. In Headache Pathogenesis: Monoamines, Neuropeptides, Purines, and Nitric Oxide, vol. 7 (Olesen, J. and Edvinsson, L., eds.), pp. 177-180, Lippincott-Raven, Philadelphia
24. 1B/1D receptor agonists in the isolated middle cerebral artery of the rat. J. Vasc. Res. 40, 561-566
25. Massen Van Den Brink, A., Reekers, M., Bax, W. A., Ferrari, M. D. and Saxena, P. R. (1998) Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98, 25-30
26. Longmore, J., Hargreaves, R. J., Boulanger, C. M. et al. (1997) Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. Funct. Neurol. 12, 3-9
27. Black, J. W. and Leff, P. (1983) Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol. Sci. 220, 141-162
28. Moller, S., Uddman, E., Welsh, N., Edvinsson, L. and Adner, M. (2002) Analysis of the time course for organ culture-induced endothelin ET B receptor upregulation in rat mesenteric arteries. Eur. J. Pharmacol. 454, 209-215
29. Friberg, L., Olesen, J., Iversen, H. K. and Sperling, B. (1991) Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 338, 13-17
30. Olesen, J., Diener, H. C., Husstedt, I. W. et al. (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350, 1104-1110
31. Petersen, K. A., Birk, S., Doods, H., Edvinsson, L. and Olesen, J. (2004) Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br. J. Pharmacol. 143, 697-704
32. McFadden, E. P., Clarke, J. G., Davies, G. J. et al. (1991) Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N. Engl. J. Med. 324, 648-654
33. McFadden, E. P., Bauters, C., Lablanche, J. M. et al. (1992) Effect of ketanserin on proximal and distal coronary constrictor responses to intracoronary infusion of serotonin in patients with stable angina, patients with variant angina, and control patients. Circulation 86, 187-195
34. Fowler, P. A., Lacey, L. F., Thomas, M. et al. (1991) The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur. Neurol. 31, 291-294
35. Rodgers, J. D., Lee, Y., Goldberg, M. R. et al. (1998) Human pharmacokinetics of rizatriptan, a 5-HT1B/1D receptor agonist. Funct. Neurol. 13, 179
36. Dixon, R. M., Meire, H. B., Evans, D. H. et al. (1997) Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia 17, 639-646